

SPEAKER: What makes it complicated in Odyssey is that not everybody got the same therapy. Because we had to treat the target approach. So there are pros and cons to both strategies using FOURIER analysis. With a FOURIER type approach, where everybody gets the same therapy, you can really well de-convolute what is more important, starting LDL, achieved LDL, or the delta. And generally, people agree that the change is probably what is the most important factor driving benefit.

The other factor, and what is very strongly obvious, both in SPIRE and in Odyssey --we're not the only ones to have found that-- is that those patients who start off with a higher baseline LDL, whom we know from previous studies and our own studies have a higher baseline risk-- for the same relative reduction, they get a greater benefit, so literally a greater bang for your buck.